BioWorld

May 27, 2009

MAP Gets Boost on Positive Phase III Migraine Study

Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives. (BioWorld Today) Read More

Cytokinetics' Cardio Bet Pays Off with Amgen Option Exercise

Cancer, Depression Have Direct Link in Cytokines, Corticosterone

United Therapeutics Jumps on Adcirca Approval in PAH

Other News To Note

Clinic Roundup

Financings Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Peptidream reveals milestone in Alnylam collaboration

BioWorld Science

Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.